{
    "clinical_study": {
        "@rank": "89197", 
        "arm_group": {
            "arm_group_label": "TAK-850 0.5 mL", 
            "arm_group_type": "Experimental", 
            "description": "A single dose of 0.5 mL TAK-850 (15 \u00b5g of hemagglutinin [HA] antigen per strain) is injected into the deltoid muscle."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial is a phase 1/2 study of a single intramuscular injection of TAK-850 in\n      healthy Japanese adult participants"
        }, 
        "brief_title": "A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study is to evaluate the safety and immunogenicity of a single\n      intramuscular injection of TAK-850  for 22 days in healthy Japanese adults"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. In the opinion of the investigator, the participant is capable of understanding\n             and complying with protocol requirements.\n\n             2. The participant signs and dates a written, informed consent form prior to the\n             initiation of any study procedures.\n\n             3. The participant is a healthy Japanese adult male or female. 4. The participant is\n             aged 20 to 49 years, inclusive, at the time of informed consent.\n\n             5. The participant has a body mass index (BMI) between 18.5 and 25.0 kg/m2,\n             inclusive, at the time of eligibility evaluation.\n\n             6. If the participant is a female of childbearing potential who is sexually active\n             with a nonsterilized male partner agrees to use routinely adequate contraception from\n             signing of informed consent throughout the duration of the study.\n\n        Exclusion Criteria:\n\n          -  1. The participant has received any investigational compound within 4 months prior to\n             the initial injection of study vaccine.\n\n             2. The participant has been vaccinated with seasonal influenza vaccine within 6\n             months prior to the initial injection of study vaccine.\n\n             3. The participant has a history of influenza infection within 6 months prior to the\n             initial injection of study vaccine 4. The participant is a study site employee, an\n             immediate family member of such an employee, or in a dependent relationship with a\n             study site employee who is involved in the conduct of this study (e.g., spouse,\n             parent, child, sibling), or may consent under duress.\n\n             5. The participant has uncontrolled, clinically significant manifestations of\n             neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal,\n             urologic, endocrine or other disorders, which may impact the ability of the\n             participant to participate or potentially confound the study results.\n\n             6. The participant has an oral temperature \u226537.5\u00b0C prior to the initial injection of\n             study vaccine on Day 1.\n\n             7. The participant has any medically diagnosed or suspected immune deficient\n             condition.\n\n             8. The participant has an immune compromising condition or disease, or is currently\n             undergoing a form of treatment or was undergoing a form of treatment that can be\n             expected to influence immune response within 30 days prior to the initial injection\n             of study vaccine. Such treatments include, but is not limited to, systemic or high\n             dose inhaled corticosteroids (>800 \u03bcg/day of beclomethasone dipropionate or\n             equivalent; the use of inhaled and nasal steroids that do not exceed this level will\n             be permitted), radiation treatment or other immunosuppressive or cytotoxic drugs.\n\n             9. The participant has received antipyretics within 4 hours prior to the initial\n             injection of study vaccine.\n\n             10. The participant has a history of Guillain- Barr\u00e9 Syndrome, demyelinating\n             disorders (including acute disseminated encephalomyelitis [ADEM] and multiple\n             sclerosis) or convulsions.\n\n             11. The participant has a functional or surgical asplenia. 12. The participant has a\n             rash, other dermatologic conditions or tattoos which may interfere with the\n             evaluation of injection site reaction as determined by the Investigator.\n\n             13. The participant has a history of, or is infected with the Hepatitis B Virus\n             (HBsAgs), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV).\n\n             14. The participant has a known hypersensitivity to any component of TAK-850. 15. The\n             participant has a history of severe allergic reactions or anaphylaxis. 16. The\n             participant has a history of drug abuse (defined as any illicit drug use) or a\n             history of alcohol abuse within 1 year prior to the initial injection of study\n             vaccine or is unwilling to agree to abstain from alcohol and drugs throughout the\n             study.\n\n             17. The participant has received any blood products (e.g. blood transfusion or\n             immunoglobulin) within 90 days prior to the initial injection of study vaccine.\n\n             18. The participant has received a live vaccine within 4 weeks (28 days) or an\n             inactivated vaccine within 2 weeks (14 days) prior to the initial injection of study\n             vaccine.\n\n             19. If female, the participant is pregnant or lactating or intending to become\n             pregnant before signing informed consent, during, or within 1 month after\n             participating in this study; or intending to donate ova during such time period.\n\n             20. The participant has donated whole blood ?200 mL within 4 weeks (28 days), \u2265400 mL\n             within 12 weeks (84 days), \u2265800 mL within 52 weeks (364 days), or blood components\n             within 2 weeks (14 days) prior to the initial injection of study vaccine.\n\n             21. The participant has abnormal (clinically significant) electrocardiogram (ECG) at\n             the assessment prior to the initial injection of study vaccine.\n\n             22. The participant has abnormal laboratory values that suggest a clinically\n             significant underlying disease at the assessment prior to the initial injection of\n             study vaccine, or the participant has the following lab abnormalities: alanine\n             aminotransferase (ALT) and/or aspartate aminotransferase (AST) more than 3 times the\n             upper limits of normal.\n\n             23. In the opinion of the investigator or subinvestigator, the participant is\n             unlikely to comply with protocol requirements or is considered ineligible for any\n             other reason."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111252", 
            "org_study_id": "TAK-850/CPH-001", 
            "secondary_id": "U1111-1153-8702"
        }, 
        "intervention": {
            "arm_group_label": "TAK-850 0.5 mL", 
            "description": "TAK-850 injection", 
            "intervention_name": "TAK-850", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug Therapy", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sumida-ku", 
                    "country": "Japan", 
                    "state": "Tokyo"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Intramuscular Injection of TAK-850 in Healthy Adult Subjects", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "+1-800-778-2860 (USA & EU)"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The frequencies of solicited local and systemic adverse events will be tabulated in its own, and by severity and day of onset.", 
                "measure": "Frequency of solicited local and systemic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "For 22 days"
            }, 
            {
                "description": "The frequencies of all adverse reactions observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, regardless of relationship to the medicinal product.", 
                "measure": "Frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "For 22 days"
            }, 
            {
                "description": "Seroprotection rate is measured by HI antibody titer for each of the three strains, 21 days after vaccination.", 
                "measure": "Seroprotection rate of hemagglutination inhibition [HI] antibody titer", 
                "safety_issue": "No", 
                "time_frame": "At Day 22"
            }, 
            {
                "description": "Seroconversion rate is measured by HI antibody titer for each of the three strains, 21 days after vaccination", 
                "measure": "Seroconversion rate of HI antibody titer", 
                "safety_issue": "No", 
                "time_frame": "At Day 22"
            }, 
            {
                "description": "Geometric mean fold increase in HI antibody titer for  each of the three strains, 21 days after vaccination, as compared to baseline.", 
                "measure": "Geometric mean fold increase in HI antibody titer", 
                "safety_issue": "No", 
                "time_frame": "At Day 22"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111252"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Vital signs will include blood pressure, pulse rate, and respiratory rate. For continuous variables, summary statistics of measured values and respective changes from baseline will be calculated at each evaluation time point. In addition, figures illustrating individual changes will be created.\nFor discrete variables, shift tables (before and after vaccination) will be created.", 
                "measure": "Change from baseline in vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "At Day 1, Day 8, Day 22"
            }, 
            {
                "description": "Laboratory values will include hematology, biochemistry and urianalysis tests. For continuous variables, summary statistics of measured values and respective changes from baseline will be calculated at each evaluation time point. In addition, figures illustrating individual changes will be created.\nFor discrete variables, shift tables (before and after vaccination) will be created.", 
                "measure": "Change from baseline in laboratory values", 
                "safety_issue": "Yes", 
                "time_frame": "At Day 1, Day 8, Day 22"
            }, 
            {
                "description": "The ECG data will be analyzed into 3 categories,  `normal`, `abonormal but not clinically significant` and `abonormal clinically significant`.\nUsing these variables, shift tables (before and after vaccination) will be created by individual participant.", 
                "measure": "Change from baseline in safety  electrocardiogram (ECG) parameters", 
                "safety_issue": "Yes", 
                "time_frame": "At Day 1 and Day 22"
            }, 
            {
                "description": "Geometric mean titer (GMT) of HI antibody titer for each of the three strains, 21 days after vaccination", 
                "measure": "Geometric mean titer (GMT) of HI antibody titer", 
                "safety_issue": "No", 
                "time_frame": "At Day 22"
            }, 
            {
                "description": "GMT of single radial hemolysis (SRH) antibody titer for each of the three strains, 21 days after vaccination.", 
                "measure": "GMT of single radial hemolysis (SRH) antibody titer", 
                "safety_issue": "No", 
                "time_frame": "At Day 22"
            }, 
            {
                "description": "Seroprotection rate is measured by SRH antibody titer for each of the three strains, 21 days after vaccination.", 
                "measure": "Seroprotection rate of  SRH antibody titer", 
                "safety_issue": "No", 
                "time_frame": "At Day 22"
            }, 
            {
                "description": "Seroconversion rate as measured by SRH antibody titer for each of the three strains, 21 days after vaccination.", 
                "measure": "Seroconversion rate of  SRH antibody titer", 
                "safety_issue": "No", 
                "time_frame": "At Day 22"
            }, 
            {
                "description": "Geometric mean fold increase in SRH antibody titer for each of the three strains, 21 days after vaccination, as compared to baseline.", 
                "measure": "Geometric mean fold increase in SRH antibody titer", 
                "safety_issue": "No", 
                "time_frame": "At Day 22"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}